Case Study: Fujirebio Diagnostics achieves real-time data management and faster study launches with ArisGlobal LifeSphere CTMS & EDC

Fujirebio Diagnostics Meets Immediate and Future Needs with LifeSphere Clinical Systems

Fujirebio Diagnostics, a global leader in in vitro diagnostics, faced rapidly growing clinical workloads and outgrew manual spreadsheet- and paper-based data processes. Led by Rachel Radwan, the U.S. clinical R&D team needed faster, more accurate data capture and streamlined data management to meet FDA submission timelines and reduce human-error risk, so they evaluated clinical platforms and selected ArisGlobal’s LifeSphere® CTMS and unified LifeSphere EDC.

ArisGlobal implemented the unified LifeSphere Clinical systems to provide real-time management of clinical operations and data, replacing manual report review and collation. The solution eliminated delays in data production and review, enabled earlier study launches and cross-study visibility (helpful during pandemic monitoring restrictions), and allowed Fujirebio Diagnostics to detect an EDC issue after 30 enrollments that would likely have taken twice as long to find with traditional methods; one study now supports over 1,000 subjects with improved execution and data quality.

Fujirebio Diagnostics

Rachel Radwan

Director of Clinical R&D